Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds
Kathryn Lagrue, Alexandre F. Carisey, David J. Morgan, et al.
Blood (2015) Vol. 126, Iss. 1, pp. 50-60
Open Access | Times Cited: 119

Showing 26-50 of 119 citing articles:

Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors
Diego Sánchez‐Martínez, Nerea Allende-Vega, Stefania Orecchioni, et al.
Theranostics (2018) Vol. 8, Iss. 14, pp. 3856-3869
Open Access | Times Cited: 57
Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing
Conor J. Kearney, Kelly M. Ramsbottom, Ilia Voskoboinik, et al.
OncoImmunology (2016) Vol. 5, Iss. 8, pp. e1196308-e1196308
Open Access | Times Cited: 49
Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy
Helmi Alfarra, Jackson A. Weir, Stacy Grieve, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 46
Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities
Noémie Leblay, Ranjan Maity, Fajer Hasan, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 39
Mechanisms of lenalidomide sensitivity and resistance
Sergio Martínez-Høyer, Aly Karsan
Experimental Hematology (2020) Vol. 91, pp. 22-31
Open Access | Times Cited: 39
The Role of the Cytoskeleton in Regulating the Natural Killer Cell Immune Response in Health and Disease: From Signaling Dynamics to Function
Aviad Ben‐Shmuel, Batel Sabag, Guy Biber, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 35
Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
Jakub Radocha, Niels W.C.J. van de Donk, Katja Weisel
Cancers (2021) Vol. 13, Iss. 7, pp. 1571-1571
Open Access | Times Cited: 34
Small Molecule Targeting Immune Cells: A Novel Approach for Cancer Treatment
Shilpi Singh, Debashis Barik, Ananta Prasad Arukha, et al.
Biomedicines (2023) Vol. 11, Iss. 10, pp. 2621-2621
Open Access | Times Cited: 14
Real-World Data on the Efficacy of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma and Amplification 1q
Magdalena Benda, Patrick Reimann, Elena Bletzacher, et al.
Cancers (2025) Vol. 17, Iss. 8, pp. 1261-1261
Open Access
Decreased CD161 activating and increased CD158a inhibitory receptor expression on NK cells underlies impaired NK cell cytotoxicity in patients with multiple myeloma
Gordana Konjević, Ana Vuletić, Katarina Mirjačić Martinović, et al.
Journal of Clinical Pathology (2016) Vol. 69, Iss. 11, pp. 1009-1016
Closed Access | Times Cited: 46
Update on the role of lenalidomide in patients with multiple myeloma
Sarah A. Holstein, Vera J. Suman, Philip L. McCarthy
Therapeutic Advances in Hematology (2018) Vol. 9, Iss. 7, pp. 175-190
Open Access | Times Cited: 46
Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell‐mediated cytotoxicity
Patrick R. Hagner, Hsiling Chiu, María Ortiz, et al.
British Journal of Haematology (2017) Vol. 179, Iss. 3, pp. 399-409
Open Access | Times Cited: 43
An actin cytoskeletal barrier inhibits lytic granule release from natural killer cells in patients with Chediak-Higashi syndrome
Aleksandra Gil‐Krzewska, Mezida B. Saeed, Anna Oszmiana, et al.
Journal of Allergy and Clinical Immunology (2017) Vol. 142, Iss. 3, pp. 914-927.e6
Open Access | Times Cited: 43
Combination lenalidomide‐rituximab immunotherapy activates anti‐tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma
Hsiling Chiu, Preeti Trisal, Chad C. Bjorklund, et al.
British Journal of Haematology (2019) Vol. 185, Iss. 2, pp. 240-253
Open Access | Times Cited: 41
Distinct Effects of Dexamethasone on Human Natural Killer Cell Responses Dependent on Cytokines
David J. Morgan, Daniel M. Davis
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 40
Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway
Leonhard Busch, Dimitrios Mougiakakos, Maike Büttner‐Herold, et al.
Leukemia (2018) Vol. 32, Iss. 11, pp. 2445-2458
Open Access | Times Cited: 40
Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them
Marco Cippitelli, Helena Stabile, Andrea Kosta, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 3, pp. 1103-1103
Open Access | Times Cited: 31
Immunomodulatory Drugs for the Treatment of B Cell Malignancies
Nikolaos Ioannou, Khushi Jain, Alan G. Ramsay
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8572-8572
Open Access | Times Cited: 31
Harnessing natural killer cells for the treatment of multiple myeloma
Joseph Clara, Richard W. Childs
Seminars in Oncology (2022) Vol. 49, Iss. 1, pp. 69-85
Open Access | Times Cited: 21
Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia
Yan Wang, Beibei Huang, Tingting Liang, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 6, pp. 101580-101580
Open Access | Times Cited: 4
A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma
Mili Arora, Sonia Gowda, Joseph M. Tuscano
Therapeutic Advances in Hematology (2016) Vol. 7, Iss. 4, pp. 209-221
Open Access | Times Cited: 37
Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma
Manh-Cuong Vo, Sung‐Hoon Jung, Tan-Huy Chu, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 36
Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma
Manh-Cuong Vo, Truc Anh-NguyenThi, Hyunju Lee, et al.
Experimental Hematology (2016) Vol. 46, pp. 48-55
Open Access | Times Cited: 33
NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment
Dang-Nghiem Vo, Catherine Alexia, Nerea Allende-Vega, et al.
OncoImmunology (2017) Vol. 7, Iss. 4
Open Access | Times Cited: 33
Translating the anti-myeloma activity of Natural Killer cells into clinical application
Cinzia Fionda, Helena Stabile, Rosa Molfetta, et al.
Cancer Treatment Reviews (2018) Vol. 70, pp. 255-264
Closed Access | Times Cited: 33

Scroll to top